Prospective evaluation of KARSARC -a gene expression-based risk classifier for patients with soft tissue sarcomas treated with pazopanib

Home » Clinical Trials » Prospective evaluation of KARSARC -a gene expression-based risk classifier for patients with soft tissue sarcomas treated with pazopanib

Research area:

Rare disease

Disease:

Soft tissue sarcomas

Intervention:

Device – In vitro diagnostic

Phase:

N/A*

Prospective evaluation of KARSARC -a gene expression-based risk classifier for patients with soft tissue sarcomas treated with pazopanib

Intervention

Device – In vitro diagnostic

Funding awarded to

The Institute of Cancer Research

Planned trial start and expected end date

July 2022 to April 2027

Prospective evaluation of KARSARC -a gene expression-based risk classifier for patients with soft tissue sarcomas treated with pazopanib

Related news

Dementia Consortium funds Manchester based team targeting immune system in search for new dementia treatments

MRC Technology invests £7 million to expand its diagnostics research capability in Scotland

UK Drug Discovery Consortium symposium